Anti-TIGIT antibody preparation

JP2025518049A5Pending Publication Date: 2026-05-22COMPUGEN
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
COMPUGEN
Filing Date
2023-05-24
Publication Date
2026-05-22

AI Technical Summary

Technical Problem

Current therapies fail to effectively target the TIGIT-PVR signaling axis, which is a major immune evasion mechanism in cancer, leading to reduced efficacy in cancer treatment.

Method used

A stable liquid pharmaceutical formulation of an anti-TIGIT antibody with specific CDRs, combined with histidine, L-arginine, L-methionine, sucrose, and polysorbate 80, is developed to enhance the antibody's stability and binding affinity to TIGIT.

Benefits of technology

The formulation provides a stable and effective anti-TIGIT antibody that maintains its binding activity and stability over a prolonged period, potentially enhancing cancer treatment outcomes by blocking the TIGIT-PVR signaling axis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000038_0000
    Figure 00000038_0000
  • Figure 00000038_0001
    Figure 00000038_0001
  • Figure 00000039_0000
    Figure 00000039_0000
Patent Text Reader

Abstract

The present invention provides a formulation comprising an anti-TIGIT antibody having the same CDR as that shown in FIG. 3 (i.e., the same CDR as that of CPA.9.086.H4 (S241P) described in this specification).
Need to check novelty before this filing date? Find Prior Art